The Indian pharmaceutical market (IPM) clocked Rs 7097 crores in August 2014 and has grown at 8.4 per cent. Amongst the top 10, Mankind grew by 15.6 per cent followed by Cipla at 14.8 per cent and Sun Pharma at 13.3 per cent. Macleods grew at 31.6 per cent to be the 10th biggest corporate. 23 corporates have crossed the growth of IPM amongst top 50.
Amongst the top 50 corporates, Akumentis has the highest growth of 57.7 per cent followed by Apex at 39.4 per cent and Macleods at 31.6 per cent. 20 corporates showed double digit growths amongst the top 50. Amongst the 11-20 ranked corporates, Macleods has the highest growth of 31.6 per cent followed by Ipca at 27.4 per cent and Intas at 19.4 per cent. Amongst the 51-60 ranked corporates, Panacea grows at 27.8 per cent followed by Allergan at 18.2 per cent and Pharmed at 16.7 per cent. Amongst the 61-75 ranked corporates, Boehringer grew by 53.8 per cent followed by Corona at 28.8 per cent and RPG at 12.6 per cent.
Indian pharma companies have grown at 9.9 per cent versus 4.4 per cent for MNCs in August 2014. Amongst the top 50 in MNCs Merck grew by 14.4 per cent followed by Ranbaxy at 10.1 per cent and Abbott at 7.8 per cent.
Under the non-NLEM category Indian companies grew at 11.2 per cent whereas MNCs grew at 5.2 per cent.
With Bonus Units at Full Value | (Val in Crs) | |||||||
Val in Crs | Rank | MAT Aug -14 | Aug-14 | |||||
CORPORATE | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 79117 | 100.00 | 7.1 | 7097 | 100.00 | 8.4 | ||
| Abbott + Abbott HC + Novo | 1 | 1 | 4966 | 6.28 | 4.1 | 441 | 6.21 | 7.8 |
| Sun Pharma | 2 | 2 | 4312 | 5.45 | 15.6 | 372 | 5.24 | 13.3 |
| Cipla | 3 | 3 | 3916 | 4.95 | 6.8 | 358 | 5.05 | 14.8 |
| Zydus + Biochem | 4 | 4 | 3445 | 4.35 | 7.0 | 297 | 4.19 | 4.8 |
| Ranbaxy | 5 | 6 | 2871 | 3.63 | 3.1 | 261 | 3.68 | 10.1 |
| Mankind | 6 | 5 | 2827 | 3.57 | 6.6 | 271 | 3.82 | 15.6 |
| Alkem + Cachet + Indchemie | 7 | 8 | 2705 | 3.42 | 6.8 | 245 | 3.45 | 2.4 |
| Glaxo | 8 | 7 | 2695 | 3.41 | -14.3 | 248 | 3.49 | 0.7 |
| Lupin | 9 | 9 | 2668 | 3.37 | 12.1 | 231 | 3.26 | 8.5 |
| Pfizer | 10 | 11 | 2305 | 2.91 | 4.2 | 204 | 2.88 | 3.2 |
| Macleods | 11 | 10 | 2205 | 2.79 | 17.1 | 222 | 3.13 | 31.6 |
| Emcure + Zuventus | 12 | 14 | 2179 | 2.75 | 11.4 | 186 | 2.63 | -0.3 |
| Intas | 13 | 12 | 2072 | 2.62 | 14.8 | 191 | 2.69 | 19.4 |
| Sanofi India | 14 | 15 | 1962 | 2.48 | -1.8 | 174 | 2.46 | 2.9 |
| Aristo | 15 | 13 | 1957 | 2.47 | 15.6 | 191 | 2.69 | 18.3 |
| Torrent | 16 | 16 | 1753 | 2.22 | 3.6 | 154 | 2.17 | 8.3 |
| Glenmark | 17 | 18 | 1715 | 2.17 | 15.4 | 152 | 2.14 | 9.0 |
| Dr. Reddys | 18 | 17 | 1698 | 2.15 | 8.6 | 153 | 2.15 | 15.2 |
| Micro + Bal | 19 | 19 | 1610 | 2.04 | 12.2 | 140 | 1.98 | 7.7 |
| Ipca | 20 | 20 | 1446 | 1.83 | 24.1 | 135 | 1.90 | 27.4 |
| USV | 21 | 21 | 1421 | 1.80 | 8.0 | 117 | 1.65 | 2.0 |
| Novartis | 22 | 24 | 1130 | 1.43 | -2.5 | 94 | 1.33 | -0.6 |
| Alembic | 23 | 23 | 1076 | 1.36 | 9.8 | 97 | 1.36 | 8.1 |
| Wockhardt | 24 | 22 | 1062 | 1.34 | 4.1 | 101 | 1.43 | 13.9 |
The DPCO 2013 containing molecules market grew at 2.9 per cent whereas the non-DPCO market grew by 9.6 per cent resulting in an overall growth of 8.4 per cent for August 2014. The NLEM category showed positive unit growth at 4.3 per cent. The DPCO 2013 portfolio for Pfizer de-grew at 17.9 per cent, GSK grew at 14.2 per cent and Ranbaxy grew by 19.5 per cent.
From therapy perspective, 10 therapies have outgrown the IPM growth and six therapies have double digit growths. Gastrointestinal market grew at 10.8 per cent, pain and analgesics market grew at 10.6 per cent, respiratory market grew at 8.5per cent whereas the anti-infectives grew at 6.4 per cent. The anti-diabetic market grows at 17.6 per cent and cardiac at 6.9 per cent in chronic business. The derma market grew by 9.8 per cent and the urology market at 17.3 per cent.
From regional perspective, 14 regions have outgrown the IPM growth. The Jharkhand market grew the highest at 21.2 per cent followed by Madhya Pradesh market at 17 per cent and Uttarakhand-UP West market at 16 per cent. One region had negative growth in August 2014.
Amoxycillin + Clavulanic Acid market grows at 24.4 per cent whereas Glimepiride + Metformin grows at 6.9 per cent at number two. The markets of paracetamol grew at 19.5 per cent, Atorvastatin 13.8 per cent, Azithromycin at 22.2 per cent, Probiotic Microbes at 21.2 per cent, Montelukast + Levocetrizine at 21.1 per cent, Glimepiride + Metformin + Pioglitazone at 40.8 per cent, Vitamin-D at 27.6 per cent, Hydroquinone + Mometasone + Tretinoin at 18.9 per cent, Voglibose + Metformin + Glimepiride at 30.1 per cent, Telmisartan + Metoprolol at 39.8 per cent.
Val in Crs | MAT Aug 14 | Month Aug-14 | ||
Super Group | Val in Crs | GR% | Val in Crs | GR% |
| IPM | 79117 | 7.1 | 7097 | 8.4 |
| ANTI-INFECTIVES | 12750 | -0.2 | 1219 | 6.4 |
| GASTRO INTESTINAL | 9047 | 8.4 | 834 | 10.8 |
| CARDIAC | 9844 | 8.9 | 824 | 6.9 |
| VITAMINS / MINERALS / NUTRIENTS | 7042 | 7.8 | 641 | 9.2 |
| RESPIRATORY | 6115 | 7.8 | 534 | 8.5 |
| PAIN / ANALGESICS | 5694 | 6.1 | 527 | 10.6 |
| ANTI DIABETIC | 5793 | 18.5 | 519 | 17.6 |
| NEURO / CNS | 4952 | 7.3 | 418 | 5.8 |
| DERMA | 4471 | 14.6 | 399 | 9.8 |
| GYNAECOLOGICAL | 4104 | 2.4 | 353 | 3.4 |
| OPHTHAL / OTOLOGICALS | 1433 | 9.8 | 127 | 9.9 |
| ANTI-NEOPLASTICS | 1278 | 26.6 | 119 | 27.5 |
| HORMONES | 1319 | 2.9 | 115 | 7.1 |
| VACCINES | 1142 | -9.0 | 89 | -15.3 |
| BLOOD RELATED | 988 | 3.5 | 86 | 0.6 |
| OTHERS | 924 | 5.7 | 85 | 4.8 |
| UROLOGY | 802 | 15.0 | 75 | 17.3 |
| ANTI MALARIALS | 615 | 2.5 | 67 | 5.1 |
| SEX STIMULANTS / REJUVENATORS | 447 | 2.7 | 35 | -0.3 |
| STOMATOLOGICALS | 357 | 10.9 | 31 | 10.1 |
Mixtard continues to lead the pack with Rs 32 crores in August 2014 with a growth of 17.5 per cent. Augmentin grows at 72.8 per cent, followed by Becosules at 29.2 per cent and Dexorange at 17.7 per cent amongst the top 10 brands.
Amongst the brands who have gained ranks include Augmentin & Lantus (+9), Galvus Met (+22), Skinlite (+14), Moxikind CV (+6), Zincovit (+12), Thyronorm (+41), Novomix (+10), SpasmoProxyvon Plus (+191), Panderm Plus (+104), Dolo (+21), Jalra M (+28), amongst top 100 Brands over August 2013.
Brands broken into top 200 include RB Tone, Econorm, Onglyza, Sporlac, Montair LC, Refresh Tears, P(Apex) over last year August 2013.
Amongst the top brands in the IPM, Galvus Met (47.6per cent), Duphaston (29.2 per cent), Lantus (19.7 per cent), Pan (18.2 per cent), Glycomet GP (17.7 per cent), Skinlite (17 per cent) grew fastest amongst top 30 brands over August 2013.
A total of 147 brands were launched in August 2014. Cefokem, Glimisave Max and Normoz are the top NIs for the month of August 2014.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
- Advertisement -